Top Stories
Atropos' predictive algorithms form the foundation of the clinical decision support solution, designed to identified underdiagnosed or undertreated patients.
The PD-L1 inhibitor is cleared for use in patients with muscle-invasive bladder cancer who have molecular residual disease following surgery.
The ECG2Stroke model was trained and validated on data from more than 200,000 patients.
The diagnostic is the first AI-powered digital pathology prognostic test to receive the designation for bladder cancer.
Up to 71% of clinically significant lung nodules lack appropriate follow-up, while high-risk pulmonary embolism patients can face treatment delays.
Conference News
Innovative design improves visibility in the lung periphery while eliminating challenges associated with balloons used during EBUS proceduresLEXINGTON, Mass.--(BUSINESS WIRE)-- FUJIFILM Healthcare Ame...
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted trea...
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted trea...
May 18, 2026From imaging to AI-enabled guidance, Philips connects technologies into a unified workflow to improve efficiency, reduce radiation exposure and support procedural confidenceAmsterdam, the ...
May 18, 2026 Greater differentiation of clinical details through contrast-rich images with reduced background noiseFor coronary procedures, a new ultra-low dose protocol employs over 50% less X-r...
